Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Addex Therapeutics Ltd. Sponsored ADR ADXN

Healthcare  —  Biotechnology
3.65 0.19 5.49% as of 25 Sep
Market cap
$3.6M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Business Profile

Updated before January 2025

Company Overview

Addex Therapeutics Ltd. Sponsored ADR (ADXN) is a clinical-stage pharmaceutical company headquartered in Geneva, Switzerland. Founded in 2002, the company specializes in the development of innovative therapies for neurological disorders and other diseases with high unmet medical needs. Addex Therapeutics is a pioneer in the field of allosteric modulation, a cutting-edge approach to drug discovery and development. The company’s leadership team includes experienced professionals in the pharmaceutical and biotechnology industries, with Tim Dyer serving as the Chief Executive Officer (CEO). Under his guidance, Addex has established itself as a leader in the development of allosteric modulators, leveraging its proprietary discovery platform to create novel treatments.

Core Business Segments

Addex Therapeutics focuses on the discovery and development of allosteric modulators, which are small molecules that bind to a site on a receptor distinct from the active site. This approach allows for more precise modulation of receptor activity, potentially leading to improved efficacy and safety profiles. The company’s core business segments include:

Neurological Disorders

Addex is actively developing therapies for neurological conditions such as Parkinson’s disease, epilepsy, and schizophrenia. Key products in this segment include:

  • Dipraglurant: A metabotropic glutamate receptor 5 (mGlu5) negative allosteric modulator (NAM) being developed for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID).
  • ADX71149: A metabotropic glutamate receptor 2 (mGlu2) positive allosteric modulator (PAM) targeting epilepsy and anxiety-related disorders.

Rare Diseases

The company is also exploring treatments for rare diseases, leveraging its expertise in allosteric modulation to address conditions with limited therapeutic options.

Research Collaborations

Addex collaborates with leading pharmaceutical companies and academic institutions to expand its pipeline and accelerate the development of innovative therapies. These partnerships enable the company to access additional resources and expertise, enhancing its ability to bring new treatments to market.

Business Model

Addex Therapeutics operates on a business model that combines in-house research and development with strategic partnerships. The company generates revenue through:

  • Licensing Agreements: Addex licenses its proprietary allosteric modulator technologies to pharmaceutical partners, receiving upfront payments, milestone payments, and royalties on sales.
  • Collaborative Research: The company engages in joint research projects with partners, sharing costs and resources to advance drug development.
  • Grants and Funding: Addex secures funding from government agencies and non-profit organizations to support its research initiatives.

This hybrid model allows Addex to maintain a robust pipeline of drug candidates while minimizing financial risk.

Strategic Direction

Addex Therapeutics is committed to advancing its pipeline of allosteric modulators and expanding its therapeutic focus. Key strategic priorities include:

  • Pipeline Expansion: The company aims to develop additional drug candidates targeting neurological disorders, rare diseases, and other therapeutic areas.
  • Global Partnerships: Addex seeks to establish new collaborations with pharmaceutical companies and academic institutions to accelerate drug development and commercialization.
  • Sustainability Goals: The company is dedicated to conducting its operations in an environmentally responsible manner, minimizing its carbon footprint, and promoting sustainable practices.
  • Innovation: Addex continues to invest in its proprietary discovery platform, enhancing its ability to identify and develop novel allosteric modulators.

Competitive Landscape

Addex Therapeutics operates in a highly competitive pharmaceutical industry, facing competition from both established companies and emerging biotech firms. Key competitors include:

  • Neurocrine Biosciences: A leader in the development of treatments for neurological and endocrine disorders.
  • Acadia Pharmaceuticals: Specializes in therapies for central nervous system disorders.
  • Sage Therapeutics: Focuses on developing treatments for brain health disorders.

Despite the competition, Addex differentiates itself through its expertise in allosteric modulation and its proprietary discovery platform.

Risk Factors

Like any pharmaceutical company, Addex Therapeutics faces several risks, including:

  • Regulatory Challenges: The drug development process is subject to stringent regulatory requirements, which can delay or prevent product approvals.
  • Market Dependence: The company’s success depends on the commercial viability of its drug candidates, which may face competition or fail to meet market expectations.
  • Supply Chain Disruptions: Addex relies on third-party suppliers and manufacturers, making it vulnerable to supply chain disruptions.
  • Financial Risks: As a clinical-stage company, Addex may require additional funding to support its operations and advance its pipeline.

Recent Developments

Addex Therapeutics has made significant progress in advancing its pipeline and strengthening its position in the market. Recent developments include:

  • Clinical Trials: The company has initiated Phase II clinical trials for Dipraglurant in Parkinson’s disease levodopa-induced dyskinesia.
  • Partnerships: Addex has entered into new collaborations with leading pharmaceutical companies to accelerate the development of its drug candidates.
  • Technological Advancements: The company has enhanced its proprietary discovery platform, enabling the identification of novel allosteric modulators.

Investment Considerations

Investors considering Addex Therapeutics should weigh the following factors:

Strengths

  • Innovative Technology: Addex’s proprietary discovery platform and expertise in allosteric modulation provide a competitive edge.
  • Strong Pipeline: The company has a robust pipeline of drug candidates targeting high-value therapeutic areas.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies enhance Addex’s resources and capabilities.

Risks

  • Clinical and Regulatory Risks: The success of Addex’s drug candidates depends on the outcomes of clinical trials and regulatory approvals.
  • Financial Uncertainty: As a clinical-stage company, Addex may face challenges in securing sufficient funding.
  • Market Competition: The pharmaceutical industry is highly competitive, with numerous players targeting similar therapeutic areas.

Conclusion

Addex Therapeutics Ltd. Sponsored ADR (ADXN) is a pioneering pharmaceutical company specializing in allosteric modulation. With a strong pipeline of drug candidates, strategic partnerships, and a commitment to innovation, Addex is well-positioned to address unmet medical needs and drive future growth. However, investors should carefully consider the risks associated with clinical-stage companies and the competitive landscape. Overall, Addex represents a promising opportunity for those seeking exposure to the biotechnology sector.